KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 5,520,000 shares, a growth of 12.2% from the March 15th total of 4,920,000 shares. Based on an average daily volume of 809,700 shares, the short-interest ratio is currently 6.8 days.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $11.74 on Tuesday. KalVista Pharmaceuticals has a one year low of $7.21 and a one year high of $16.88. The stock has a market cap of $495.31 million, a PE ratio of -3.73 and a beta of 0.88. The firm has a 50 day simple moving average of $12.96 and a two-hundred day simple moving average of $11.22.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). On average, research analysts expect that KalVista Pharmaceuticals will post -3.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KALV has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $35.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, April 11th.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 4,474 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 6th. The stock was purchased at an average price of $14.74 per share, for a total transaction of $65,946.76. Following the completion of the purchase, the insider now directly owns 4,743,157 shares of the company’s stock, valued at $69,914,134.18. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, major shareholder Venrock Healthcare Capital Par acquired 4,474 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, February 6th. The stock was bought at an average price of $14.74 per share, with a total value of $65,946.76. Following the completion of the purchase, the insider now owns 4,743,157 shares in the company, valued at $69,914,134.18. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Benjamin L. Palleiko sold 22,802 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $14.11, for a total transaction of $321,736.22. Following the transaction, the chief financial officer now directly owns 187,315 shares of the company’s stock, valued at approximately $2,643,014.65. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 246,907 shares of company stock worth $3,304,971 and sold 75,978 shares worth $1,070,918. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Point72 Hong Kong Ltd bought a new stake in KalVista Pharmaceuticals in the second quarter worth $26,000. Quantbot Technologies LP purchased a new stake in KalVista Pharmaceuticals during the third quarter valued at about $31,000. Royal Bank of Canada boosted its position in KalVista Pharmaceuticals by 225.7% during the second quarter. Royal Bank of Canada now owns 4,492 shares of the specialty pharmaceutical company’s stock valued at $40,000 after buying an additional 3,113 shares during the period. Tower Research Capital LLC TRC boosted its position in KalVista Pharmaceuticals by 28.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock valued at $43,000 after buying an additional 768 shares during the period. Finally, Barclays PLC boosted its position in KalVista Pharmaceuticals by 148.1% during the fourth quarter. Barclays PLC now owns 6,572 shares of the specialty pharmaceutical company’s stock valued at $45,000 after buying an additional 3,923 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.